EX-99 2 immucellcorporation.htm IMMUCELL CORPORATION PRESS RELEASE

ImmuCell Announces Financial Results for 2009

PORTLAND, ME -- (Marketwire - February 10, 2010) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the quarter and year ended December 31, 2009.

For the three-month period ended December 31, 2009, product sales decreased by 17%, or $213,000, to $1,034,000 in comparison to the same period in 2008. For the year ended December 31, 2009, product sales decreased by 3%, or $122,000, to $4,506,000 in comparison to 2008.

"I resist the temptation to blame everything negative on the condition of the global economy that may be in the early stages of a recovery. However, a product sales decrease of only 2.6% in 2009 is pretty good news for us, given that our customers had to manage through a 35% reduction in the average milk price during 2009, in comparison to the average price of 2007 and 2008," commented Michael F. Brigham, President and CEO. "We announced a significant milestone for ImmuCell on September 30, 2009 with positive results from the pivotal effectiveness study of Mast Out®."

Product development expenses decreased by 22%, or $111,000, to $395,000 during the three-month period ended December 31, 2009 in comparison to the same period in 2008. Product development expenses decreased by 6%, or $101,000, to $1,645,000 during the year ended December 31, 2009 in comparison to 2008. Product development expenses amounted to 37% and 38% of product sales during the years ended December 31, 2009 and 2008, respectively.

The loss before income taxes was $(89,000) during the three-month period ended December 31, 2009 in comparison to a loss before income taxes of $(251,000) during the same period in 2008. The net loss was $(15,000), or $(0.01) per share, during the three-month period ended December 31, 2009 in comparison to a net loss of $(40,000), or $(0.01) per share, during the same period in 2008.

The loss before income taxes was $(428,000) during the year ended December 31, 2009 in comparison to a loss before income taxes of $(961,000) during 2008. The net loss was $(216,000), or $(0.07) per share, during the year ended December 31, 2009 in comparison to a net loss of $(469,000), or $(0.16) per share, during 2008.

"After nine consecutive years of profitability, our losses before income taxes in 2008 and 2009 reflect our strategic decision to make a significant and controlled investment in the development of Mast Out®," added Mr. Brigham.

Cash, cash equivalents and short-term investments decreased by 9%, or $469,000, to $4,585,000 at December 31, 2009 as compared to $5,054,000 at December 31, 2008. Stockholders' equity decreased by less than 1%, or $22,000, to $9,622,000 at December 31, 2009 as compared to $9,644,000 at December 31, 2008. The Company had 2,971,000 shares of common stock outstanding as of December 31, 2009.

                                       (Unaudited)
                                    Three Months Ended  Twelve Months Ended
                                       December 31,        December 31,
(In thousands, except per share     ------------------  ------------------
 amounts)                             2009      2008      2009      2008
                                    --------  --------  --------  --------
Revenues:
Product Sales                       $  1,034  $  1,247  $  4,506  $  4,628
Other Revenues                            --         1         3         5
                                    --------  --------  --------  --------
Total Revenues                         1,034     1,248     4,509     4,633

Cost and expenses:
Product costs                            443       677     2,108     2,559
Product development expenses             395       506     1,645     1,746
Selling, general and administrative
 expenses                                296       357     1,283     1,496
                                    --------  --------  --------  --------
Total costs and expenses               1,134     1,540     5,036     5,801
                                    --------  --------  --------  --------

Net operating loss                      (100)     (292)     (527)   (1,168)

Interest and other income                 11        41        99       207
                                    --------  --------  --------  --------

Loss before income taxes                 (89)     (251)     (428)     (961)
Income tax benefit                        74       211       212       492
                                    --------  --------  --------  --------
Net loss                            $    (15) $    (40) $   (216) $   (469)
                                    ========  ========  ========  ========

Net loss per common share:
Basic                               $  (0.01) $  (0.01) $  (0.07) $  (0.16)
Diluted                             $  (0.01) $  (0.01) $  (0.07) $  (0.16)
                                    ========  ========  ========  ========

Weighted average common shares
 outstanding:
Basic                                  2,971     2,895     2,959     2,894
Diluted                                2,971     2,895     2,959     2,894


                                       At December 31,  At December 31,
(In thousands)                               2009             2008
                                       --------------   --------------
Cash, cash equivalents and short-term
 investments                           $        4,585   $        5,054
Total assets                                    9,985           10,128
Net working capital                             5,944            6,245
Stockholders' equity                   $        9,622   $        9,644

ImmuCell Corporation is a biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our revised web-site (http://www.immucell.com) that was launched on January 28, 2010.

Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106



The following information was filed by Immucell Corp (ICCC) on Wednesday, February 10, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Immucell Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Immucell Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

FREE Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue for FREE

Log in with your credentials

or    

Forgot your details?

Create Account